The manufacturer behind the Ozempic weight loss drug has asked a federal court to prohibit a Houston-area pharmacy from selling compounded, non-FDA-approved medications purported to contain the drug’s key ingredient. The request was filed in response to allegations that the pharmacy is producing and distributing a knockoff version of Ozempic, which could result in significant implications for both regulatory compliance and patient safety.
For more detailed information, the Law360 article can be accessed here.